(STE) STERIS - Overview
Stock: Sterilization, Disinfection, Surgical Equipment, Contract Services
| Risk 5d forecast | |
|---|---|
| Volatility | 25.4% |
| Relative Tail Risk | -6.20% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.03 |
| Alpha | -7.64 |
| Character TTM | |
|---|---|
| Beta | 0.469 |
| Beta Downside | 0.327 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.87% |
| CAGR/Max DD | 0.57 |
EPS (Earnings per Share)
Revenue
Description: STE STERIS March 02, 2026
STERIS plc (NYSE: STE) is a global provider of infection-prevention solutions, organized into three core segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment supplies cleaning chemistries, endoscope reprocessing systems, and a full suite of sterile-processing equipment and services for hospitals. AST offers contract sterilization and testing for medical-device and pharmaceutical makers, together with integrated sterilization hardware. The Life Sciences segment manufactures consumables such as pharmaceutical detergents, clean-room disinfectants, vapor-phase hydrogen-peroxide systems, and high-purity water generators, plus related installation and maintenance services.
In FY 2025 STE reported revenue of $4.2 billion, up 7 % year-over-year, driven by strong demand for infection-control products amid heightened antimicrobial-resistance concerns and expanding hospital procedural volumes. Operating margin improved to 13 % and diluted EPS reached $3.45, while free cash flow of $450 million supported a $1.1 billion backlog of capital-equipment orders. Sector-wide, U.S. healthcare capital expenditures are projected to grow 4-5 % annually through 2028, and the pharmaceutical contract-manufacturing market is expanding at ~6 % CAGR, both bolstering STE’s growth tailwinds.
For a deeper dive, you may want to explore ValueRay’s analyst notes.
Headlines to watch out for
- Healthcare equipment sales and service contracts drive revenue
- Contract sterilization demand from medical device manufacturers
- Life Sciences consumables and equipment sales grow
- Regulatory changes impact infection prevention product demand
- Hospital capital expenditure trends influence equipment sales
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 707.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 1.15 > 1.0 |
| NWC/Revenue: 23.40% < 20% (prev 19.76%; Δ 3.64% < -1%) |
| CFO/TA 0.12 > 3% & CFO 1.27b > Net Income 707.8m |
| Net Debt (1.63b) to EBITDA (1.36b): 1.20 < 3 |
| Current Ratio: 2.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (98.8m) vs 12m ago -0.14% < -2% |
| Gross Margin: 44.11% > 18% (prev 0.43%; Δ 4367 % > 0.5%) |
| Asset Turnover: 56.58% > 50% (prev 50.91%; Δ 5.67% > 0%) |
| Interest Coverage Ratio: 11.64 > 6 (EBITDA TTM 1.36b / Interest Expense TTM 62.7m) |
Altman Z'' 4.39
| A: 0.13 (Total Current Assets 2.29b - Total Current Liabilities 922.3m) / Total Assets 10.59b |
| B: 0.27 (Retained Earnings 2.86b / Total Assets 10.59b) |
| C: 0.07 (EBIT TTM 730.2m / Avg Total Assets 10.30b) |
| D: 2.09 (Book Value of Equity 7.15b / Total Liabilities 3.42b) |
| Altman-Z'' Score: 4.39 = AA |
Beneish M -3.07
| DSRI: 0.95 (Receivables 990.6m/915.2m, Revenue 5.83b/5.10b) |
| GMI: 0.98 (GM 44.11% / 43.38%) |
| AQI: 0.94 (AQ_t 0.57 / AQ_t-1 0.60) |
| SGI: 1.14 (Revenue 5.83b / 5.10b) |
| TATA: -0.05 (NI 707.8m - CFO 1.27b) / TA 10.59b) |
| Beneish M-Score: -3.07 (Cap -4..+1) = AA |
What is the price of STE shares?
Over the past week, the price has changed by -6.97%, over one month by -5.83%, over three months by -11.60% and over the past year by +0.55%.
Is STE a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the STE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 281.3 | 22% |
| Analysts Target Price | 281.3 | 22% |
STE Fundamental Data Overview March 05, 2026
P/E Forward = 22.7273
P/S = 4.0981
P/B = 3.3965
P/EG = 1.8925
Revenue TTM = 5.83b USD
EBIT TTM = 730.2m USD
EBITDA TTM = 1.36b USD
Long Term Debt = 1.90b USD (from longTermDebt, last quarter)
Short Term Debt = 34.4m USD (from shortTermDebt, last quarter)
Debt = 2.05b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.63b USD (from netDebt column, last quarter)
Enterprise Value = 25.51b USD (23.88b + Debt 2.05b - CCE 423.7m)
Interest Coverage Ratio = 11.64 (Ebit TTM 730.2m / Interest Expense TTM 62.7m)
EV/FCF = 27.82x (Enterprise Value 25.51b / FCF TTM 917.1m)
FCF Yield = 3.59% (FCF TTM 917.1m / Enterprise Value 25.51b)
FCF Margin = 15.74% (FCF TTM 917.1m / Revenue TTM 5.83b)
Net Margin = 12.14% (Net Income TTM 707.8m / Revenue TTM 5.83b)
Gross Margin = 44.11% ((Revenue TTM 5.83b - Cost of Revenue TTM 3.26b) / Revenue TTM)
Gross Margin QoQ = 43.81% (prev 44.23%)
Tobins Q-Ratio = 2.41 (Enterprise Value 25.51b / Total Assets 10.59b)
Interest Expense / Debt = 0.72% (Interest Expense 14.8m / Debt 2.05b)
Taxrate = 24.63% (63.5m / 257.8m)
NOPAT = 550.4m (EBIT 730.2m * (1 - 24.63%))
Current Ratio = 2.48 (Total Current Assets 2.29b / Total Current Liabilities 922.3m)
Debt / Equity = 0.29 (Debt 2.05b / totalStockholderEquity, last quarter 7.17b)
Debt / EBITDA = 1.20 (Net Debt 1.63b / EBITDA 1.36b)
Debt / FCF = 1.78 (Net Debt 1.63b / FCF TTM 917.1m)
Total Stockholder Equity = 6.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.87% (Net Income 707.8m / Total Assets 10.59b)
RoE = 10.21% (Net Income TTM 707.8m / Total Stockholder Equity 6.93b)
RoCE = 8.27% (EBIT 730.2m / Capital Employed (Equity 6.93b + L.T.Debt 1.90b))
RoIC = 6.21% (NOPAT 550.4m / Invested Capital 8.87b)
WACC = 7.09% (E(23.88b)/V(25.94b) * Re(7.65%) + D(2.05b)/V(25.94b) * Rd(0.72%) * (1-Tc(0.25)))
Discount Rate = 7.65% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.28%
[DCF] Terminal Value 84.29% ; FCFF base≈850.8m ; Y1≈1.05b ; Y5≈1.79b
[DCF] Fair Price = 360.7 (EV 37.00b - Net Debt 1.63b = Equity 35.37b / Shares 98.1m; r=7.09% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 78.20 | EPS CAGR: 5.91% | SUE: 0.0 | # QB: 0
Revenue Correlation: 76.65 | Revenue CAGR: 5.81% | SUE: 0.13 | # QB: 0
EPS next Quarter (2026-06-30): EPS=2.51 | Chg7d=-0.022 | Chg30d=-0.022 | Revisions Net=-2 | Analysts=7
EPS next Year (2027-03-31): EPS=11.10 | Chg7d=-0.037 | Chg30d=-0.037 | Revisions Net=-3 | Growth EPS=+8.8% | Growth Revenue=+6.3%
[Analyst] Revisions Ratio: -0.33 (2 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.0% (Discount Rate 7.9% - Earnings Yield 3.0%)
[Growth] Growth Spread = +1.7% (Analyst 6.7% - Implied 5.0%)